Recent advances in triple negative breast cancer: the immunotherapy era
Open Access
- 9 May 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in BMC Medicine
- Vol. 17 (1), 1-9
- https://doi.org/10.1186/s12916-019-1326-5
Abstract
Several accomplishments have been achieved in triple-negative breast cancer (TNBC) research over the last year. The phase III IMpassion130 trial comparing chemotherapy plus atezolizumab versus chemotherapy plus placebo brought breast cancer into the immunotherapy era. Nevertheless, despite encouraging results being obtained in this trial, many open questions remain. A positive overall survival outcome was achieved only in PD-L1+ TNBC patients, suggesting a need to enrich the patient population more likely to benefit from an immunotherapeutic approach. Moreover, it remains unknown whether single-agent immunotherapy might be a good option for some patients. In this context, the discovery and implementation of novel and appropriate biomarkers are required. Focusing on the early onset of TNBC, neoadjuvant trials could represent excellent in vivo platforms to test immunotherapy agents and their potential combinations, allowing the performance of translational studies for biomarker implementation and improved patient selection. The aim of our review is to present recent advances in TNBC treatment and to discuss open issues in order to better define potential future directions for immunotherapy in TNBC.Keywords
This publication has 68 references indexed in Scilit:
- PD-L1 Expression as a Predictive Biomarker in Cancer ImmunotherapyMolecular Cancer Therapeutics, 2015
- PD-L1 Expression in Triple-Negative Breast CancerCancer Immunology Research, 2014
- Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung CancerClinical and Developmental Immunology, 2014
- Effects of conventional therapeutic interventions on the number and function of regulatory T cellsOncoImmunology, 2013
- Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancerClinical and Translational Oncology, 2013
- Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivoCancer Immunology, Immunotherapy, 2012
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor BearersClinical Cancer Research, 2010
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor ImmunityCancer Research, 2010
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006